key: cord-0864412-liz16wg6
authors: Neves, Precil D.; Caires, Renato A.; Guimarães, Manoel P.; Costalonga, Elerson C.; Cavalcante, Livia B.; Costa e Silva, Verônica T.; Mattedi, Francisco Z.; Santana, Leonardo F.; Teixeira-Júnior, Antônio A.; Gomes, Orlando V.; Silva, Gyl E.; Burdmann, Emmanuel A.; Onuchic, Luiz F.
title: Collapsing Glomerulopathy following SARS-CoV-2 adenovirus-vector based vaccine: report of two cases
date: 2022-01-04
journal: Kidney Int
DOI: 10.1016/j.kint.2021.12.016
sha: 213d555c5424164e395a40a0acd97a2bc6e301b0
doc_id: 864412
cord_uid: liz16wg6

nan

In the setting of the rapid spread of the pandemic by the new coronavirus (COVID-19) and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the kidney was recognized as a frequent target. 1 With the beginning of vaccination for COVID-19, several cases of post-vaccination immunological manifestations have been described. 2 We report herein the first two cases of patients who developed biopsy-proven CG after SARS-CoV-2 adenovirus-vector based vaccination.

A 63-year-old afro-descendant female presented to hospital complaining of edema of ankle, foamy urine for three months, which began nine days after receiving the first dose Oxford-AstraZeneca COVID-19 vaccine. She had a previous diagnosis of hypertension, heart failure and dyslipidemia and reported that one month after the onset of symptoms she presented to the emergency department (ED) due to dyspnea. On that occasion, the patient underwent a chest x-ray that evidenced a pleural effusion and COVID-19 serology thar was negative for IgM and IgG. She was diagnosed with acutely decompensated heart failure, and she treated with diuretics. Until the current hospital admission, she returned to ED another 2 times, maintaining negative serologies for COVID-19 and pleural effusion. On physical examination at admission, she presented edema (+2/+4) in the lower limbs, blood pressure of 150 / 98 mmHg.

Laboratory tests revealed hemoglobin: 11.8g/dL; leukocytes: 6.930/mm3, platelets: 240,000/mm3; urea: 19.8mg/dL, creatinine: 0.88mg/dL, eGFR by CKD-EPI: 70mL/min/1.73m2, urinalysis: proteins +3 and red cells +2, proteinuria: 4131mg/day, and there were no evidence of electrolyte or acid-base abnormalities. Albumin 2.7g/dL, total cholesterol: 405mg/dL, LDL: 294mg/dL, HDL 75mg/dL; Triglycerides: 216mg/dL. Serological tests for Chagas, schistosomiasis, HIV, hepatitis B and C, and VDRL were negative. Serology for COVID-19 -IgM: 0.61AU/mL / IgG: 0.14 AU/mL (normal range:

Cut-off-index < 1.0AU/mL). Renal biopsy revealed at light microscopy glomeruli with synechiae and segmental sclerosis lesions, with some of them showing collapse of capillary loops in addition to podocyte hyperplasia and hypertrophy ( Figure 1A -B). The tubulointerstitial compartment revealed mild tubular degeneration. Immunofluorescence microscopy highlighted deposits of IgM +2/+3 and C3 +2/+3 ( Figure 1C) , with a segmental and focal pattern upon the sclerotic sites. Histological J o u r n a l P r e -p r o o f 4 (anthracycline, pamidronate and interferon) and infections (HIV, hepatitis B and C, parvovirus B19, cytomegalovirus, Epstein-Barr virus). 3, 4 We presented herein the first two cases of CG following a SARS-CoV-2 adenovirus-vector based vaccine (SVBV). In the first case, the patient presented only one risk allele for APOL1, that based on current medical literature is not associated do increased risk of renal disease. In the second case, the patient presented a HRG-APOL1, a genetic condition that have previously been associated with increased risk of CG and CKD. Interestingly, those disorders may manifest following exposure to environmental triggers. S1,S2 The proposed susceptibility and triggering mechanisms support a double-hit mechanism for the genesis of CG. S1 The podocyte injury in genetically susceptible individuals with CG may be cytokine mediated.

There is growing evidence linking CG to conditions that increased Interferon (IFN) levels (such as infections and exogenous IFN therapy) in both patients with and without HRG-APOL1. S12

There are several reports of glomerulopathies arising within three weeks of SARS-CoV-2 immunization, with most cases arising within the first week, S5 but this is the description of two first cases of CG associated with SARS-CoV-2 immunization that symptoms had started 1-2 weeks after vaccination. Most reports have been associated with mRNA vaccines, but at least three cases were related to SVBV. S4,S5

From the immunological viewpoint, the development of glomerular diseases shortly after SARS-CoV-2 immunization implies T cells as effectors S4 . Following injection, SVBV target innate immune cells like dendritic cells and macrophages and engage multiple pattern-recognition receptors that bind dsDNA to induce IFN secretion, which can trigger podocytopathies in the susceptible patient or amplify quiescent glomerular diseases. S6 Another potential mechanism for glomerular injury is a molecular mimicry between SARS-CoV-2 spike protein and self-antigens on the podocytes. S4 Since IFN pathways have an important role in the pathogenesis of CG, notably in patients homozygous for APOL1 high risk variants, their stimulation by SARS-CoV-2 immunization could be a potential second-hit triggering CG development, especially among genetic susceptible patients.

Finally, we believe that risks of glomerular injury development should not prevent the use of SARS-CoV-2 vaccines. SARS-CoV-2 immunization must not be avoided based on the fear of triggering or worsening a glomerulopathy.

J o u r n a l P r e -p r o o f

São Paulo, Brazil 2. Nephrology and Dialysis Center

Renal Morphology in Coronavirus Disease: A Literature Review

Membranous nephropathy following anti-COVID-19 mRNA vaccination

Collapsing glomerulopathy: update

Schistosoma mansoni infection as a trigger to collapsing glomerulopathy in a patient with high-risk APOL1 genotype